BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

...Giovanna Lombardi, Alberto Sanchez-Fueyo, Elmar Jaeckel, Hans Stauss, Emma Morris, Marc Martinez-Llordella, Iain McGillAcademic collaborators: King's College London...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...LIfT, King's College partner on iPS cell-derived antitumor neutrophils LIfT BioSciences Ltd. partnered with King's College London...
...Transforming growth factor β 1 BioCentury Staff Berkeley Lights Inc. New York University Langone Medical Center University of Maryland King's College London Vanderbilt...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting PARP for pathologic vascular calcification

...email: cathy.shanahan@kcl.ac.uk CONTACT: Melinda J. Duer, University of Cambridge, Cambridge, U.K. email: mjd13@cam.ac.uk Claire Quang Dynacin, Minocin (minocycline) King's College London University...
BioCentury | May 20, 2019
Financial News

Syncona launches Treg company Quell with £35 million A round

...Quell Therapeutics Ltd. (London, U.K.) has in-licensed IP developed by its six academic co-founders from King's College London...
...to Quell in March. Petris declined to give additional financial terms. Mark Zipkin, Staff Writer Hannover Medical School King's College London Syncona...
BioCentury | May 8, 2019
Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

...corticosteroids could normalize the altered cell signaling observed. microRNA stimulates cell regeneration after heart attack King's College London...
...Programmed cell death 1; PLC1 gamma - Phospholipase C1 gamma Mary Romeo, Staff Writer Fudan University Harvard University King's College London Moderna...
BioCentury | Mar 26, 2019
Distillery Therapeutics

Pore-forming peptide for multiple bacterial infections

...J. Am. Chem. Soc. ; published online March 6, 2019 doi:10.1021/jacs.8b11939 CONTACT: Charles H. Chen, King's College London...
...above email: martin.ulmschneider@kcl.ac.uk CONTACT: Jakob P. Ulmschneider, Shanghai Jiao Tong University, Shanghai, China email: jakob@sjtu.edu.cn Claire Quang King's College London Shanghai...
BioCentury | Mar 8, 2019
Company News

Merck partners with King’s College to develop non-opioid pain therapies

...Merck has partnered with King's College London to translate research elucidating HCN2 as a pain target to develop...
...develop selective HCN2 inhibitors that avoid similar off-target effects (see Distillery ). Elizabeth S. Eaton, Staff Writer King's College London Merck...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...CARsgen Therapeutics Co. Ltd. CAR-CLD18 Gastric cancer; pancreatic cancer Ph I EGFR, HER2 and HER3 King's College London...
BioCentury | Oct 11, 2018
Translation in Brief

Public funding highlights: 3Q18

...£14 million ($18.3 million) center in London to connect academics from University College London , King's College London...
Items per page:
1 - 10 of 112
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

...Giovanna Lombardi, Alberto Sanchez-Fueyo, Elmar Jaeckel, Hans Stauss, Emma Morris, Marc Martinez-Llordella, Iain McGillAcademic collaborators: King's College London...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...LIfT, King's College partner on iPS cell-derived antitumor neutrophils LIfT BioSciences Ltd. partnered with King's College London...
...Transforming growth factor β 1 BioCentury Staff Berkeley Lights Inc. New York University Langone Medical Center University of Maryland King's College London Vanderbilt...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting PARP for pathologic vascular calcification

...email: cathy.shanahan@kcl.ac.uk CONTACT: Melinda J. Duer, University of Cambridge, Cambridge, U.K. email: mjd13@cam.ac.uk Claire Quang Dynacin, Minocin (minocycline) King's College London University...
BioCentury | May 20, 2019
Financial News

Syncona launches Treg company Quell with £35 million A round

...Quell Therapeutics Ltd. (London, U.K.) has in-licensed IP developed by its six academic co-founders from King's College London...
...to Quell in March. Petris declined to give additional financial terms. Mark Zipkin, Staff Writer Hannover Medical School King's College London Syncona...
BioCentury | May 8, 2019
Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

...corticosteroids could normalize the altered cell signaling observed. microRNA stimulates cell regeneration after heart attack King's College London...
...Programmed cell death 1; PLC1 gamma - Phospholipase C1 gamma Mary Romeo, Staff Writer Fudan University Harvard University King's College London Moderna...
BioCentury | Mar 26, 2019
Distillery Therapeutics

Pore-forming peptide for multiple bacterial infections

...J. Am. Chem. Soc. ; published online March 6, 2019 doi:10.1021/jacs.8b11939 CONTACT: Charles H. Chen, King's College London...
...above email: martin.ulmschneider@kcl.ac.uk CONTACT: Jakob P. Ulmschneider, Shanghai Jiao Tong University, Shanghai, China email: jakob@sjtu.edu.cn Claire Quang King's College London Shanghai...
BioCentury | Mar 8, 2019
Company News

Merck partners with King’s College to develop non-opioid pain therapies

...Merck has partnered with King's College London to translate research elucidating HCN2 as a pain target to develop...
...develop selective HCN2 inhibitors that avoid similar off-target effects (see Distillery ). Elizabeth S. Eaton, Staff Writer King's College London Merck...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...CARsgen Therapeutics Co. Ltd. CAR-CLD18 Gastric cancer; pancreatic cancer Ph I EGFR, HER2 and HER3 King's College London...
BioCentury | Oct 11, 2018
Translation in Brief

Public funding highlights: 3Q18

...£14 million ($18.3 million) center in London to connect academics from University College London , King's College London...
Items per page:
1 - 10 of 112